Allucent

Tune into our recent webinar (https://lnkd.in/gauPtb9Y) by Allucent VP, Clinical Pharmacology, Devin Welty, PhD, discussing the role of translational clinical pharmacology in cell and gene therapy trials. Translational clinical pharmacology plays an integral role in the success of first-in-human AAV and CAR-T therapies, ensuring that groundbreaking treatments can effectively meet patients' needs while maintaining rigorous safety standards. You'll learn more about: - The rapid growth and subsequent challenges in cell and gene therapy - Role of translational clinical pharmacology in advancing AAV and CAR-T Therapies Don't miss out on this opportunity to gain valuable insights on the implementation of translational clinical pharmacology from an industry expert! #Allucent #BringNewTherapiesToLight #Pharmacology #DrugDiscovery #ClinicalTrials

How can you ensure your clinical development plan will set you up for success? https://lnkd.in/gfmvezr7 Read these insights from Allucent regulatory experts (and previous FDA reviewer) to learn how.   A clinical development plan (CDP) is a comprehensive document that presents a holistic strategy for developing an investigational product from preclinical testing to market authorization. In this blog, you will not only learn about the fundamentals of the CDP but also strategies to optimize your plan. Hear from the experts, Sugato De (VP, Regulatory Strategy, Head of Medtech), Joshua Taylor, PhD, RAC Taylor (Sr. Director, Regulatory Affairs), Lisa Sanders (Sr. Director, Regulatory Affairs), and John McIntyre, PhD McIntyre (Director, Clinical Strategy). (To access the full infographic shown in the picture, go to the blog link above.) #Allucent #BringNewTherapiesToLight #ClinicalDevelopment #Biotech #RegulatoryAffairs

Allucent is excited to announce the promotion of Howard Brand from VP of Finance to Chief Financial Officer.   Howard boasts over 20 years of experience in the CRO industry. His extensive background in helping companies succeed during periods of hypergrowth is invaluable as Allucent continues to flourish. #Allucent #BringNewTherapiesToLight #CRO #DrugDiscovery #ClinicalTrials

How can small biotech companies overcome some of the unique challenges in their clinical product development programs? Read our newest blog to learn more: https://lnkd.in/gjXmBnhq Small biotechnology companies remain a significant force in the #drugdevelopment market, representing 77% of active products in development. Impactful challenges persist, like rising #clinicaltrial costs, resource scarcity, fierce competition, and limited financing availability. Read insights from our Allucent Biometrics expert José Matamoros Luna, MSc (Sr. Clinical Data Manager II) on overcoming some of these challenges faced by small #biotechs today. #Allucent #BringNewTherapiesToLight #DrugDevelopment #ClinicalTrials #DataManagement #Biotech

We're so proud to have someone of Anita Nelsen's caliber lead our clinical trial operations. In this short BiotechTV snippet, Anita talks about how Allucent's passion to help small and mid-size biotechs develop therapies in complex and challenging disease indications; support our customers with the latest technologies including cell and gene therapy; and help them navigate the patient journey. #ClinicalTrial #ClinicalResearch #PatientSafety

Allucent is thrilled to announce our selection by the Biomedical Advanced Research and Development Authority (BARDA) for the new Decentralized Clinical Operations for Healthcare and Research (D-COHRe) initiative.   This initiative aims to enhance decentralized clinical study capabilities to support and accelerate the development of medical countermeasures (MCMs) and strengthening the nation's preparedness and response to future public health emergencies (PHEs)   Through the D-COHRe program, Allucent will leverage the shift toward decentralized healthcare and enhance decentralized clinical study capabilities in order to build sustainable frameworks and evaluate medical countermeasures in real world environments. Mark A. Goldberg, MD Learn more: https://lnkd.in/gqrZdwXy #Allucent #BringNewTherapiesToLight #BARDA #ClinicalDevelopment #DecentralizedTrials #Healthcare

Meet Dr. Elizabeth Hussey, PharmD, VP, Clinical Pharmacology. Dr. Hussey has deep expertise, garnered over 30 years of professional experience in drug development, clinical development, clinical pharmacology, and pharmacokinetics across multiple therapeutic areas and all phases of development. She has therapeutic experience in dermatology, metabolic disease, CNS, and antimicrobials among other things. We're so grateful to have Dr. Hussey on the A Team! #Allucent #BringNewTherapiesToLight #Pharmacology #ClinicalPharmacology #DrugDevelopment 

For important industry highlight explore Allucent’s Newsletter: https://lnkd.in/gg26wk2i For Business Queries, contact us: https://lnkd.in/gzwJy62X #Allucent #Oncology #DrugDevelopment #ClinicalResearch #BringNewTherapiesToLight #HealthcareInnovation

Allucent is wishing a safe and wonderful 4th of July to all those who will be celebrating! We hope that you get the chance to spend time with loved ones, eat good food, and relax this holiday weekend. #Allucent #BringNewTherapiesToLight #IndependenceDay #FourthofJuly

Sponsoring clinical pharmacology (PK/PD) fellowships is an important part of Allucent’s investment in young scientists. They help us establish important connections with academia and demonstrates our commitment to advancing scientific knowledge and investment in professional development, while Fellows gain critical skills in research and development, PK/PD and modeling work experience, their research opportunities potentially leading to new discoveries, best practices and innovations. Today, we say goodbye and recognize the contributions of one Fellow, while welcome and look forward to the impact of a new one to the Allucent family. A graduate from the University of North Texas Health Science Center, Jeanne Dulie Kom Nzia, PharmD, recently completed her UNC/Allucent PK/PD and Innovation Fellowship with us. During her time at Allucent, Jeanne succeeded working on a number of clinical pharmacology and pharmacometrics projects, including clin pharm consulting for development of a fixed-dose combination and developing templates for clinical pharmacology study synopses. And now, we welcome Li Chen, who earned her PharmD from the University of Michigan and comes to us having completed her first year at the University of North Carolina Eshelman School of Pharmacy. Her research experience includes the Effects of the Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Antitumor Response of Anetumab Ravtansine in Patients with Solid Tumors (to be presented at 2024 ACCP Annual Meeting, Sept 8-10 Bethesda, MD.) Her projects at Allucent will include pharmacometrics and clinical pharmacology strategy. #Allucent #BringNewTherapiesToLight #Pharmacology #PBPK #DrugDevelopment